RECRUITING Phase 1 ClinicalTrials.gov

A Study of KK2269 in Adult Participants With Solid Tumors

Sponsor: Kyowa Kirin Co., Ltd. • ClinicalTrials.gov ID: NCT06266299

Registry updated: 2026-09-10

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269. In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies. In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible.

Interventions

KK2269 (Drug)
KK2269 administered intravenously
Docetaxel (Drug)
antineoplastic drug administered intravenously

Eligibility criteria

* Key Common Inclusion Criteria for Parts 1 and 2: * Patients who are ≥ 18 years old at the time of informed consent * Patients who have disease measurable by RECIST v1.1 * Patients with an ECOG PS of 0 or 1 * Patients with a life expectancy of at least 3 months in the judgement of the investigator or subinvestigator * The specified periods have passed respectively after the completion of previous cancer treatments as of the date of enrollment at the time of the first dose of KK2269 * Patients who agree to use a medically effective method of contraception * Key Additional Inclusion Criterion for Part 1: •Patients with histological or cytological evidence of at least one locally advanced or metastatic non-CNS solid tumor * Key Additional Inclusion Criteria for Part 2: •Patients with histological or cytological evidence of any of the following disease: Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal adenocarcinoma, NSCLC (Only patients with NSCLC will be enrolled in the expansion part) •Patients who are suitable for docetaxel treatment * Key Common Exclusion Criteria for Parts 1 and 2: * Patients with an uncontrolled or serious intercurrent illness * Patients with known active central nervous system metastasis * Patients with a history of ≥ Grade 3 allergic reaction to any antibody drug * Patients with a history of autoimmune disease * Patients with a history of HIV, HBV, or HCV at screening * Patients who have a history of primary immunodeficiency * Key Additional Exclusion Criterion For Part 2: * Patients with a history of treatment with docetaxel

Conditions

Advanced Solid Tumor Metastatic Solid Tumor Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma Non Small Cell Lung Cancer

Locations

Mayo Clinic Arizona — Scottsdale, Arizona, United States
City Of Hope National Medical Center — Duarte, California, United States
Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
Mayo Clinic Jacksonville — Jacksonville, Florida, United States
Washington University — St Louis, Missouri, United States
The University of Texas Southwestern Medical Center — Dallas, Texas, United States
University of Washington — Seattle, Washington, United States
Aichi Cancer Center — Nagoya, Aichi-ken, Japan
Fujita Health University Hospital — Toyoake, Aichi-ken, Japan
National Cancer Center Hospital East — Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center — Matsuyama, Ehime, Japan
Kurume University Hospital — Kurume, Fukuoka, Japan
Kobe Minimally Invasive Cancer Center — Kobe, Hyōgo, Japan
Kanagawa Cancer Center — Yokohama, Kanagawa, Japan
Kansai Medical University Hospital — Hirakata, Osaka, Japan
Kindai University Hospital — Sakai, Osaka, Japan
NHO Kinki-Chuo Chest Medical Center — Sakai, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital — Takatsuki, Osaka, Japan
Saitama Prefectural Cancer Center — Shinden, Saitama, Japan
Shizuoka Cancer Center — Nagaizumi-chō, Shizuoka, Japan
Tochigi Cancer Center — Utsunomiya, Tochigi, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital — Bunkyō-Ku, Tokyo, Japan
National Cancer Center Hospital — Chuo-ku, Tokyo, Japan
Cancer Institute Hospital of JFCR — Koto-Ku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center — Fukuoka, Japan
Hiroshima University Hospital — Hiroshima, Japan
Kumamoto University Hospital — Kumamoto, Japan
Nagasaki University Hospital — Nagasaki, Japan
Niigata Cancer Center Hospital — Niigata, Japan
Okayama University Hospital — Okayama, Japan
Osaka International Cancer Institute — Osaka, Japan
Toyama University Hospital — Toyama, Japan

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment